Skip to content

Educational reference only. Not medical advice, diagnosis, or treatment, and not dosing, injection, or purchasing guidance.Medical disclaimer

Research-use labeling in the United States

The project list asked for the U.S. legal status of research-use peptides. This draft only records one FDA statement. It is not that full analysis.

  • FDA says it has warned companies that illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide, or mazdutide that were falsely labeled “for research purposes” or “not for human consumption.”
  • FDA says those products have been sold directly to consumers for human use with dosing instructions, and that they are of unknown quality and may be harmful.
  • A separate FDA guidance on research-use-only labeling, and the text of sections 503A and 503B, were not opened for this draft.

Do not read this page as permission to sell or buy a product labeled for research.

This page does not give doses, titration schedules, injection or implantation technique, preparation steps, or places to purchase a product.

Page record

  • Type: Regulation
  • Domain: peptides
  • Evidence: Not rated
  • Status: reviewed
  • Last reviewed: 2026-11-20

Regulatory status: Partial note only. FDA research-use-only guidance was not opened for this draft.

Sources

Referenced by

A link from another wiki page is not evidence. Facts should point at the sources above.